EUVIMEDEUVIMED entdecken
Crossref

Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

Maria Elena Maccari, Martin Wolkewitz, Charlotte Schwab, Tiziana Lorenzini, Jennifer W Leiding, Nathalie Aladjdi, Hassan Abolhassani, Wadih Abou-Chahla, Alessandro Aiuti, Saba Azarnoush, Safa Baris, Vincent Barlogis und 48 weitere

Journal of Allergy and Clinical Immunology · 2023-10 · 152 (4) · 984-996.e10

DOI: 10.1016/j.jaci.2023.06.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-10. Verfasst von Maria Elena Maccari und 59 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freibu…. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinase, Primary Immunodeficiency Diseases. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Medical Research Council, Wellcome Trust, KU Leuven.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Activated phosphoinositide-3-kinase δ syndrome (APDS) is an inborn error of immunity (IEI) with infection susceptibility and immune dysregulation, clinically overlapping with other conditions. Management depends on disease evolution, but predictors of severe disease are lacking. OBJECTIVES: This study sought to report the extended spectrum of disease manifestations in APDS1 versus APDS2; compare these to CTLA4 deficiency, NFKB1 deficiency, and STAT3 gain-of-function (GOF) disease; and identify predictors of severity in APDS. METHODS: Data was collected from the ESID (European Society for Immunodeficiencies)-APDS registry and was compared with published cohorts of the other IEIs. RESULTS: The analysis of 170 patients with APDS outlines high penetrance and early onset of APDS compared to the other IEIs. The large clinical heterogeneity even in individuals with the same PIK3CD variant E1021K illustrates how poorly the genotype predicts the disease phenotype and course. The high clinical overlap between APDS and the other investigated IEIs suggests relevant pathophysiological convergence of the affected pathways. Preferentially affected organ systems indicate specific pathophysiology: bronchiectasis is typical of APDS1; interstitial lung disease and enteropathy are more common in STAT3 GOF and CTLA4 deficiency. Endocrinopathies are most frequent in STAT3 GOF, but growth impairment is also common, particularly in APDS2. Early clinical presentation is a risk factor for severe disease in APDS. CONCLUSIONS: APDS illustrates how a single genetic variant can result in a diverse autoimmune-lymphoproliferative phenotype. Overlap with other IEIs is substantial. Some specific features distinguish APDS1 from APDS2. Early onset is a risk factor for severe disease course calling for specific treatment studies in younger patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasePrimary Immunodeficiency DiseasesHumansPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesCTLA-4 AntigenMutationRegistries

Stichwörter der Autor:innen

APDSCTLA4ESIDIEINFKB1PI3KPIK3CDPIK3R1STAT3immunodeficiency

Substanzen

Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesCTLA-4 Antigen

Autor:innen und Institutionen

  • Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Division of Pediatric Hematology and Oncology,…
  • Institute of Medical Biometry and Statistics, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Pediatrics and Adolescent Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Pediatrics Clinic and Institute for Molecular M…
  • Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
  • Pediatric Haemato-Immunology, Clinical Investigation Center (CIC) 1401, Institut National de la Santé et de la Recherche Médicale (INSERM) Centre d'Investigation Clinique Pluridisciplinaire (CICP), Bordeaux University H…

Förderung

  • Medical Research Council
  • Wellcome Trust
  • KU Leuven
  • Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca
  • Ospedale Pediatrico Bambino Gesù
  • Swiss National Science Foundation
  • BMBF Bonn
  • Swedish Research Council

Zitieren

APA

Maccari, M. E., Wolkewitz, M., Schwab, C., Lorenzini, T., Leiding, J. W., Aladjdi, N., Abolhassani, H., Abou-Chahla, W., Aiuti, A., Azarnoush, S., Baris, S., Barlogis, V., Barzaghi, F., Baumann, U., Bloomfield, M., Bohynikova, N., Bodet, D., Boutboul, D., Bucciol, G., …, & Lougaris, V. (2023). Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. Journal of Allergy and Clinical Immunology, 152(4), 984-996.e10. https://doi.org/10.1016/j.jaci.2023.06.015

Vancouver

Maccari ME, Wolkewitz M, Schwab C, Lorenzini T, Leiding JW, Aladjdi N, et al. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. Journal of Allergy and Clinical Immunology. 2023;152(4):984-996.e10. doi:10.1016/j.jaci.2023.06.015

BibTeX
@article{Maccari2023,
  author = {Maccari, Maria Elena and Wolkewitz, Martin and Schwab, Charlotte and Lorenzini, Tiziana and Leiding, Jennifer W and Aladjdi, Nathalie and Abolhassani, Hassan and Abou-Chahla, Wadih and Aiuti, Alessandro and Azarnoush, Saba and Baris, Safa and Barlogis, Vincent and Barzaghi, Federica and Baumann, Ulrich and Bloomfield, Marketa and Bohynikova, Nadezda and Bodet, Damien and Boutboul, David and Bucciol, Giorgia and Buckland, Matthew S and Burns, Siobhan O and Cancrini, Caterina and Cathébras, Pascal and Cavazzana, Marina and Cheminant, Morgane and Chinello, Matteo and Ciznar, Peter and Coulter, Tanya I and D'Aveni, Maud and Ekwall, Olov and Eric, Zelimir and Eren, Efrem and Fasth, Anders and Frange, Pierre and Fournier, Benjamin and Garcia-Prat, Marina and Gardembas, Martine and Geier, Christoph and Ghosh, Sujal and Goda, Vera and Hammarström, Lennart and Hauck, Fabian and Heeg, Maximilian and Heropolitanska-Pliszka, Edyta and Hilfanova, Anna and Jolles, Stephen and Karakoc-Aydiner, Elif and Kindle, Gerhard R and Kiykim, Ayca and Klemann, Christian and Koletsi, Patra and Koltan, Sylwia and Kondratenko, Irina and Körholz, Julia and Krüger, Renate and Jeziorski, Eric and Levy, Romain and Le Guenno, Guillaume and Lefevre, Guillaume and Lougaris, Vassilios},
  title = {Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {4},
  pages = {984--996.e10},
  doi = {10.1016/j.jaci.2023.06.015}
}
Kostenlos starten →